Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin

Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutrali s ing Affimer Therapy